Year: 2017
Type: review
Abstract: Cancer is the second leading cause of death worldwide, and it is estimated that Human papillomavirus (HPV) related cancers account for 5% of all human cancers. Current HPV vaccines are extremely effective at preventing infection and neoplastic disease; however, they are prophylactic and do not clear established infections. Therapeutic vaccines which trigger cell-mediated immune responses for the treatment of established infections and malignancies are therefore required. The E6 and E7 early genes are ideal targets for vaccine therapy due to their role in disruption of the cell cycle and their constitutive expression in premalignant and malignant tissues. Several strategies have been investigated for the development of therapeutic vaccines, including live-vector, nucleic acid, peptide, protein-based and cell-based vaccines as well as combinatorial approaches, with several vaccine candidates progressing to clinical trials. With the current understanding of the HPV life cycle, molecular mechanisms of infection, carcinogenesis, tumour biology, the tumour microenvironment and immune response mechanisms, an approved HPV therapeutic vaccine seems to be a goal not far from being achieved. In this article, the status of therapeutic HPV vaccines in clinical trials are reviewed, and the potential for plant-based vaccine production platforms described.
Source: Papillomavirus Research
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Keywords: therapeutic vaccines, human papillomavirus, HPV-associated cancers, HPV E6 and E7 oncoproteins, cell-mediated immunity, live vector vaccine, nucleic acid vaccines, peptide vaccine, protein-based vaccines, cell-based vaccine, plant-based vaccine production, tumor microenvironment, HPV oncogenesis, clinical trials
Open Access status: gold
Estimated APC paid: $900
Award: G8751799850
OpenAlex ID: W2776284875
